3 Cannabis Themes to Know: From a Goldman Sachs Upgrade to Canadian M&A Activity
December 14, 2017
2017 has been a great year for cannabis investors and expect 2018 to be even more significant.
From Germany distributing medical marijuana licenses to Canada’s recreational marijuana market opening, there is a lot for investors to look forward to.
Yesterday, the cannabis sector was under pressure while the overall market traded higher and we are monitoring how the sector moves today. Canadian licensed producers pulled back and momentum has been trending lower since late November.
We have highlighted 3 significant developments that investors need to be aware of. From a Goldman Sachs (GS) upgrade to a surprising CEO change, we are monitoring the cannabis sector closely today.
GW Pharma: Receives a Major Boost from Goldman Sachs
GW Pharmaceuticals (GWPH) received a major boost for Goldman Sachs and we expect to see the biotech firm to rally on this development.
This morning, Goldman upgraded GW from Hold to Buy and increased its price target to $174 from $124. This is a significant upgrade and expect to see GW rally on this news. Goldman Sachs is one of the most highly followed broker-dealers and has one of the top equity research teams in the world.
When Goldman Sachs speaks, investors listen and we expect GW to record a solid gain today. We are bullish on GW’s long-term outlook due to its pipeline of cannabinoid therapies in advanced stages of FDA testing, its cash position, and its growth opportunity. We consider GW to be an acquisition candidate and are favorable at current levels.
MassRoots: Announces a New Board and CEO
Isaac Dietrich is back in control of MassRoots (MSRT).
This development follows a very volatile and confusing two months where Dietrich was removed as the company’s CEO.
Effective December 12th, Ean Seeb, Vincent (Tripp) Keber, and Terence Fitch resigned as members of MassRoots’ Board of Directors. Cecil Kyte, Nathan Shelton and Charles Blum were appointed to fill these openings on the company’s Board.
MassRoots has taken shareholders on a bumpy ride and we continue to monitor this situation. We have taken a more cautious approach with the cannabis technology company and will keep the stock on our radar. We are interested on seeing what happens with the previously announced initiatives now that Dietrich is back at the helm.
Canadian Cannabis Stocks Continue to Shine
Although the Canadian cannabis sector was under pressure yesterday, we remain favorable on the long-term outlook and view this weakness as transitory. Canadian licensed producers have recorded significant gains over the last quarter and pullbacks of this nature are healthy for a long-term rally. Momentum has been trending lower and we are monitoring this metric closely. Once momentum finds a bottom, we expect to see the sector enter another growth cycle which will beneficial for investors.
Over the last month, inorganic growth initiatives (i.e. acquisitions) have taken center stage and we expect this trend to significantly accelerate during the next year. We are monitoring CanniMed’s (CMED.TO) (CMMDF) attempt to fend off an acquisition by Aurora Cannabis (ACB.TO) (ACBFF) and expect this deal to go through. If the deal is shot down by the courts, we would not be surprised if Aurora targeted a new company for acquisition.
Yesterday, Aphria (APH.TO) (APHQF) announced a $100 million bought deal financing and we expect to see the licensed medical marijuana producers use these proceeds to make acquisitions in Canada and abroad (we expect them to target Germany).
Canopy Growth (WEED.TO) (TWMJF) has also been expanding through acquisitions and has used its stock as a currency. We are favorable on this approach since the company will retain its cash for growth initiatives.
We remain bullish on Canadian licensed producers and consider the following companies to be acquisition targets: Emblem (EMC.V) (EMMBF), Organigram (OGI.V) (OGMRF), Emerald Health (EMH.V) (EMHTF), Invictus MD Strategies (IMH.V) (IVITF), and Supreme Pharmaceuticals (FIRE.V) (SPRWF).
აბა ინგლისურის მცოდნეებო თარგმნეტ და დადეთ
არა აქვს კავშირი გოლდმან საქსს კანაბისტანო
ეს არის საინვესტიციო კომპანიაც რომელიც ინვესტიციებს გასცემს სხვადასხვა სფეროებში მათ შორის სამედიცინო მარიხუანას სფეროში
ესეც გოლდმან საქსის ვეტერანი გადასული კანაპის ბიზნესში
ასე რომ ნურაფერი გიკვირთ
Goldman Sachs Veteran Joins Cannabis Investment Firm
April 11, 2018 at 6:47 am
Published by NCV Newswire
FacebookTwitterLinkedInReddit
April 11, 2018, CHICAGO–(BUSINESS WIRE)–Salveo Capital, an alternative investment firm specializing in the legalized cannabis space, today announced the appointment of Thomas Mazarakis as a Managing Partner. Mr. Mazarakis will work alongside Managing Partners Michael Gruber and Jeffrey Howard in overseeing strategic direction and will be responsible for portfolio management as well as scaling the firm and its operations.
Mr. Mazarakis, 47, has over 18 years of financial and investment experience. Most recently, Mr. Mazarakis served as a Managing Director at Goldman Sachs in London where he was head of the Fundamental Strategies Group, a department of research analysts within the securities division’s multi-billion dollar equity and credit businesses. Earlier in his career at Goldman Sachs, Mr. Mazarakis served as an Executive Director and led the retail/consumer sector team. Prior to his tenure at Goldman Sachs, Mr. Mazarakis spent two years at Citigroup in New York where he analyzed high yield and distressed industrial companies within the credit research department. Mr. Mazarakis received a Bachelor of Science in environmental engineering from Northwestern University and a MBA from the University of Michigan.
Tom is a seasoned financial professional who brings years of relevant experience and a strong track record to Salveo. We expect Tom’s fundamentals-driven research process and analytical background to add a significant level of rigor and diligence to the cannabis fund landscape. We are very much looking forward to Tom’s contributions to our portfolio companies, fund investors and the firm as a whole.
Michael C. Gruber, a Managing Partner of Salveo Capital
“We are thrilled to welcome Tom as we seek to build premier companies to help reshape the image of legalized cannabis,” added Jeffrey Howard, a Managing Partner of Salveo Capital. “As the legalized cannabis space continues to evolve, it is critical that we have the right people in place to help us capitalize on strategic investment opportunities. As an avid early-stage investor and advisor to high-growth companies who is knowledgeable and passionate about the industry, Tom is the ideal fit to support our mission and goals.”
I am excited to have the opportunity to join a well-regarded firm that is investing in and partnering with innovative companies and entrepreneurs within a unique and high-growth sector. Michael and Jeff have worked diligently in a short time frame to assemble a high-quality portfolio of companies that is performing very well and has significant upside potential. I look forward to working with the team and building on this momentum.
Thomas Mazarakis, Managing Partner
Salveo Capital’s primary investment focus is on high-growth, ancillary service providers to the cannabis industry – rather than more highly-regulated businesses that “touch the plant”. The firm is currently investing capital out of its first private equity fund (“Fund I”) and is targeting a $25 million close in mid-2018. Salveo is seeking to rapidly scale its platform with a goal of reaching $100 million of committed capital by 2019. Thus far, Salveo Capital has completed seven investments including Baker, Front Range Biosciences, Headset, Purissima, Hiku Brands (formerly Tokyo Smoke), Treez and Wurk. Legalized cannabis is a $9 billion market in North America and, according to industry research, is expected to reach an estimated $22 billion by 2020. From an international perspective, various countries around the world including Australia, Germany and Spain are legalizing marijuana, while others including Canada, Israel and The Netherlands are permitting exportation.
About Salveo Capital
Launched at the end of 2016, Salveo Capital is an alternative investment firm specializing in the legalized cannabis space, particularly ancillary businesses. Salveo Capital’s approach is to bring an institutional quality discipline to company vetting, investment structures and portfolio management. The Firm is committed to shaping the early-stage, yet rapidly growing, industry by providing funding and development to companies with the will and vision to be the future faces of legalized marijuana. As cannabis legalization spreads, Salveo Capital seeks to build long term sustainable companies and support innovative technologies, products and services to help address the unique requirements of the industry. The firm is based in Northbrook, Illinois, and with vertical industry executives and cannabis operating advisors across the country, including key markets of California and Colorado. For more information, please visit www.salveocapital.com.
Original press release
ბატონი ბიბინი ბევრს იცნობს
პა ხოდუ მაგან სამება ააშენა
This post has been edited by Hermosa on 13 Sep 2018, 08:57 
ივანიშვილი კანაფის ბიზნესით დაკავებული ამერიკული, კომპანიის აქციების მფლობელია
